Literature DB >> 3892697

Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.

R L Capizzi, B L Powell, M R Cooper, J J Stuart, H B Muss, F Richards, D V Jackson, D R White, C L Spurr, P J Zekan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3892697

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  5 in total

Review 1.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 2.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

3.  A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.

Authors:  E Kurrle; G Ehninger; M Freund; G Heil; D Hoelzer; H Link; P S Mitrou; S Ohl; W Queisser; G Schlimok
Journal:  Blut       Date:  1988-05

Review 4.  Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside.

Authors:  R L Capizzi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.